A US firm claims its coronavirus vaccine could prevent 94.5% of people from getting the disease.

Data from Moderna suggests its vaccine works across all age groups, including the elderly.

The UK has not placed an order for the vaccine – which works in a similar way to Pfizer's and is said to be generally safe and well-tolerated – and it is unclear whether the British Government can get any stock.

However, a Government spokesperson told LBC they "are in advanced talks with Moderna on a Covid-19 vaccine”.

Thirty-thousand people were given the vaccine in the US in a trial, and preliminary analysis was based on the first 95 to develop Covid-19 symptoms.

The UK has not placed an order for the Moderna vaccine

Just five had symptoms after taking the vaccine, and the other 90 had been given the placebo.

Moderna said the vaccine protected 94.5% of people.

There were 11 cases of severe coronavirus in the trial, but none occurred in those who were immunised.

Scientists said the news bodes well for other Covid-19 vaccines, with the one for Oxford University and UK pharmaceutical giant AstraZeneca due to report in the coming days or weeks.

Moderna intends to submit an application for an Emergency Use Authorisation with the US Food and Drug Administration shortly and will submit further data on the vaccine's effectiveness and safety.

However, a Government said they 'are in advanced talks with Moderna on a Covid-19 vaccine'

Any side effects were mild or moderate in severity, Moderna said.

Severe events after the first dose included injection site pain and after the second dose included fatigue, myalgia (muscle pain), arthralgia (joint pain), headache, pain, and redness at the injection site.

But these effects of the injection were generally short-lived, Moderna said.

Chief Executive Officer Stephane Bancel said: "This is a pivotal moment in the development of our Covid-19 vaccine candidate.

Its final-stage critical trial involves 30,000 people in the US

"Since early January, we have chased this virus with the intent to protect as many people around the world as possible.

"All along, we have known that each day matters.

"This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent Covis-19 disease, including severe disease."

Scientists said the news bodes well for other Covid-19 vaccines

Last week, pharmaceutical giant Pfizer said its vaccine is more than 90% effective based on initial trial results.

Pfizer and German partner BioNTech expect to seek US emergency use authorisation this month.

If granted, the companies estimate they can roll out up to 50 million doses this year, enough to protect 25 million people, and then produce up to 1.3 billion doses in 2021.

Health Secretary Matt Hancock today told BBC Breakfast that Britain is “working very closely” with Pfizer to roll out the vaccine as early as the start of December.